That Novartis AG’s IgA nephropathy (IgAN) candidate iptacopan hit on proteinuria in its Phase III trial is good news, as far as it goes, but that is not very far. Without the extent of the product’s success over placebo having been disclosed, it is hard to gauge the drug’s effectiveness versus its peers.
Key Takeaways
- Novartis is seeking accelerated approval for iptacopan in IgAN after an interim Phase III hit
The hit ought to be good enough to secure accelerated approval for iptacopan in the kidney disease. But Novartis’s chances...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?